John Bernard Payne, President and CEO at Zivo Bioscience, Inc. (ZIVO), bought 57 shares at $2.50 ($143) on 2022-12-19, disclosed to the SEC on 2022-12-20.
Open-market purchase of $142 ZIVO by President and CEO. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| ZIVO | BUY | 2022-01-28 | $23K | — | Filing → |